Argenx's Phase 3 Study of Potential Neuromuscular Autoimmune Disease Treatment Meets Primary Endpoint

MT Newswires Live
08/25

Argenx (ARGX) said Monday that a phase 3 study of its drug Vyvgart met its primary endpoint in treating patients with AChR-Ab seronegative generalized myasthenia gravis, an autoimmune disease.

The company said patients treated with Vyvgart in the study generally showed "statistically significant and clinically meaningful" improvement over those given a placebo.

Argenx said it plans to use the results of the 119-patient study to submit a supplemental biologics license application to the US Food and Drug Administration seeking to expand Vyvgart indications label to include adults with all subtypes of the rare, neuromuscular autoimmune disease that causes potentially life-threatening muscle weakness and chronic fatigue.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10